Becton Dickinson and Co vs Workiva Inc — how do they compare? Becton Dickinson and Co trades at $181.29 (market cap $48.93B), while Workiva Inc trades at $68.78 (market cap $3.66B). The key difference: Becton Dickinson and Co is far larger — about 13.4× Workiva Inc's market cap, and Becton Dickinson and Co pays a 2.34% dividend while Workiva Inc pays none. Which is the better fit depends on your goals.
| BDX | WK | |
|---|---|---|
Market Cap | $48.93B | $3.66B |
Sector | Health | Technology |
52-Week High | $185.39 | $93.31 |
52-Week Low | $138.62 | $44.31 |
Enterprise Value | $65.03B | $3.64B |
Dividend Yield | 2.34% | — |
Signals from Pluang's Aura AI — not financial advice
BDX (Becton, Dickinson and Company) trades at $176.86, down 0.12% on the day, with a bullish technical outlook supported by moving averages and strong earnings beats in recent quarters. The company reported Q3 2026 revenue of $5.0 billion, up 4.4% FX-neutral, and raised full-year guidance, though margins faced pressure. Analyst sentiment is mixed with a consensus price target of $183.00, while institutional ownership remains stable amid positive news on GLP-1 therapy expansions and dividend declarations.
The stock offers steady growth potential with a 2.7% dividend yield and consistent earnings outperformance, but risks include margin compression, regulatory recalls, and high valuation multiples. Near-term resistance at $180 and support at $173 will test bullish momentum, with the current price near the consensus target suggesting limited upside without further catalysts.
Workiva (WK) trades at $65.14, up 4.98% with strong bullish momentum. The stock shows positive technical signals with recent earnings beats and revenue growth of 19% year-over-year in Q2 2026. Analyst consensus is overwhelmingly bullish with 16 buy ratings and an average price target of $69.00. The company's AI platform expansion and strong subscription growth support continued momentum.
Outlook remains positive with improving profitability and strategic AI investments, though high valuation multiples and RSI levels near 70 suggest potential near-term consolidation. Key risks include execution challenges and competitive pressures in the compliance software space.
Trailing returns across standard periods
Latest headlines on both assets
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →